Drug intelligence / Profile preview

CM-1212

Development stage: Preclinical
Lead developer: Curemark
Modality: Therapeutic Enzymes → Recombinant Proteins and Enzymes

Overview

CM-1212 is a discovery-stage drug candidate developed by Curemark LLC for the treatment of substance use disorders, including alcohol and drug addiction. The therapeutic approach is based on Curemark's proprietary technology involving enzyme stimulation to address gastrointestinal and pancreatic secretory deficiencies. The company focuses on the link between these deficiencies and neurological or dysautonomic symptoms, suggesting that restoring enzymatic balance may alleviate addictive behaviors. As of the latest reports, the program remains in the discovery phase of research and development.

Beyond the preview

Go deeper on CM-1212.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CM-1212.

Explore the full profile